Bessemer Group
SPRY icon

Bessemer Group’s ARS Pharmaceuticals SPRY Stock Holding History

Bessemer Group’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$60K Hold
7,525
– – ﹤0.01% 1647
2026
Q1 		$61K Buy
7,525
+7,290
+3,102% +$69.9K ﹤0.01% 1622
2025
Q4 		$3K Hold
235
– – ﹤0.01% 2370
2025
Q3 		$2K Hold
235
– – ﹤0.01% 2351
2025
Q2 		$4K Hold
235
– – ﹤0.01% 2092
2025
Q1 		$3K Sell
235
-20
-8% -$241 ﹤0.01% 2179
2024
Q4 		$3K Hold
255
– – ﹤0.01% 2158
2024
Q3 		$4K Buy
+255
New +$3.03K ﹤0.01% 2039

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Bessemer Group's SPRY Position: Q2 2026 in Review

Bessemer Group held its ARS Pharmaceuticals (SPRY) position steady in Q2 2026 at 7,525 shares worth $60K. The position accounts for ﹤0.01% of the portfolio, ranked #1647.

Bessemer Group first reported a position in SPRY in Q3 2024 and has held it in 8 quarters since. The position peaked at $61K in Q1 2026. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Bessemer Group held 7,525 shares of ARS Pharmaceuticals worth $60K as of Q2 2026.
  • Bessemer Group left its ARS Pharmaceuticals share count unchanged in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #1647 holding.
  • Bessemer Group first reported a position in ARS Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Bessemer Group's ARS Pharmaceuticals position peaked at $61K in Q1 2026.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.